← Leaderboards

Guang-Ping Gao

Univ Of Massachusetts Med Sch Worcester

Google Scholar ↗PubMed ↗ORCID ↗

$18,861,560

Attributed

$25,052,903

Total exposure

15

Grants

11

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.1M · FY2009–25

$5M$3.8M$2.5M$1.3M$0

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$25,052,903 · 15

By mechanism

P01$8,575,556 · 7

R01$8,082,409 · 2

UH3$2,938,558 · 1

UG3$2,700,237 · 1

U19$2,157,700 · 1

R21$432,018 · 1

Top collaborators

Others in their field

Top investigators on “Mediating”

Bambra Strokes · Ppd Development Lp$526,656,217
Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
Barton F Haynes · Duke University$295,802,493
Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499

Research focus

MediatingVectorCapsidGene TherapyDesignAdeno-Associated Viral VectorTransgenesBaseNonhuman PrimateIn VivoSerotypingGene TransferMacaca MulattaRecombinant Adeno-Associated Virus (Raav)CellsDoseImmunityTechnologyAnimalsPrimatesTransgene ExpressionProteinsTherapeutic GeneEvaluation

Grant awards (56)

Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and Leukodystrophies$533,982

R01 · FY2025 · NS · contact PI

Vector Immunology Core$335,000

P01 · FY2025 · HL · contact PI

Vector Immunology Core$327,205

P01 · FY2024 · HL · contact PI

Core C: Viral vector core$304,869

U19 · FY2024 · AI · contact PI

Novel Gene Therapy Strategies for Canavan Disease$422,442

R01 · FY2023 · NS · contact PI

Vector Immunology Core$335,000

P01 · FY2023 · HL · contact PI

Core C: Viral vector core$312,375

U19 · FY2023 · AI · contact PI

Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$1,660,678

UH3 · FY2022 · HL · contact PI

Novel Gene Therapy Strategies for Canavan Disease$422,442

R01 · FY2022 · NS · contact PI

Vector Immunology Core$335,000

P01 · FY2022 · HL · contact PI

Core C: Viral vector core$241,515

U19 · FY2022 · AI · contact PI

Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$1,277,880

UH3 · FY2021 · HL · contact PI

Core C: Viral vector core$984,566

U19 · FY2021 · AI · contact PI

Novel Gene Therapy Strategies for Canavan Disease$459,292

R01 · FY2021 · NS · contact PI

Vector Immunology Core$335,000

P01 · FY2021 · HL · contact PI

Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$795,706

UG3 · FY2020 · HL · contact PI

Novel Gene Therapy Strategies for Canavan Disease$459,292

R01 · FY2020 · NS · contact PI

Core C: Viral vector core$314,375

U19 · FY2020 · AI · contact PI

Viral Vector Core$224,850

P01 · FY2020 · HL · contact PI

Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$802,570

UG3 · FY2019 · HL · contact PI

Novel Gene Therapy Strategies for Canavan Disease$459,292

R01 · FY2019 · NS · contact PI

Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$275,792

UG3 · FY2019 · HL · contact PI

Viral Vector Core$224,850

P01 · FY2019 · HL · contact PI

Develop combinatorial non-viral and viral CRISPR delivery for lung diseases$826,169

UG3 · FY2018 · HL · contact PI

Next Generation of Recombinant AAV Serotype For Gene Therapy$770,648

R01 · FY2018 · HL

Viral Vector Core$192,206

P01 · FY2018 · HL · contact PI

Next Generation of Recombinant AAV Serotype For Gene Therapy$788,573

R01 · FY2017 · HL

Viral Vector Core$192,206

P01 · FY2017 · HL · contact PI

Next Generation of Recombinant AAV Serotype For Gene Therapy$622,223

R01 · FY2016 · HL

Novel gene therapy strategies for Canavan disease$472,725

R01 · FY2016 · NS · contact PI

Minimizing transgene clearance$422,213

P01 · FY2016 · AI · contact PI

AAV Core$369,436

P01 · FY2016 · AI · contact PI

Viral Vector Core$213,563

P01 · FY2016 · HL · contact PI

Next Generation of Recombinant AAV Serotype For Gene Therapy$142,500

R01 · FY2016 · HL

Next Generation of Recombinant AAV Serotype For Gene Therapy$630,906

R01 · FY2015 · HL

Novel gene therapy strategies for Canavan disease$472,725

R01 · FY2015 · NS · contact PI

Minimizing transgene clearance$382,898

P01 · FY2015 · AI · contact PI

AAV Core$306,914

P01 · FY2015 · AI · contact PI

Novel gene therapy strategies for Canavan disease$467,999

R01 · FY2014 · NS · contact PI

Minimizing transgene clearance$339,727

P01 · FY2014 · AI · contact PI

AAV Core$268,323

P01 · FY2014 · AI · contact PI

Novel gene therapy strategies for Canavan disease$454,523

R01 · FY2013 · NS · contact PI

MOLECULAR BIOLOGY OF AAV IN LIVER$450,773

P01 · FY2013 · HL · contact PI

Minimizing transgene clearance$351,891

P01 · FY2013 · AI · contact PI

Safety and efficacy of optimized AAV3 vectors in murine and NHP livers$283,018

R21 · FY2013 · EB

AAV Core$240,248

P01 · FY2013 · AI · contact PI

Minimizing transgene clearance$539,039

P01 · FY2012 · AI · contact PI

Novel gene therapy strategies for Canavan disease$502,845

R01 · FY2012 · NS · contact PI

MOLECULAR BIOLOGY OF AAV IN LIVER$463,117

P01 · FY2012 · HL · contact PI

AAV Core$329,224

P01 · FY2012 · AI · contact PI

Safety and efficacy of optimized AAV3 vectors in murine and NHP livers$149,000

R21 · FY2012 · EB

MOLECULAR BIOLOGY OF AAV IN LIVER$489,694

P01 · FY2011 · HL · contact PI

MOLECULAR BIOLOGY OF AAV IN LIVER$480,054

P01 · FY2010 · HL · contact PI

Molecular Biology of AAV in Liver$427,125

P01 · FY2009 · HL · contact PI

Core--Bioassy$166,425

P30 · FY2003 · DK

Core--Viral Vector Core$0

P30 · FY2002 · DK